Identification of pAKT as a pharmacodynamic marker for MER kinase in human melanoma G361 cells
Biomarker Research volume 8, Article number: 4 (2020)
The MER signaling pathway represents an attractive therapeutic target for human cancers. Growth arrest–specific protein 6 (GAS6)–induced MER phosphorylation is often unstable and difficult to detect without pervanadate pretreatment in human cancer cells, posing a challenge for the development of selective MER kinase inhibitors. Here, we identified phosphorylated AKT (pAKT) as a specific pharmacodynamic marker for MER kinase inhibitors in human melanoma G361 cells.
The expression of MER, TYRO3, and AXL were profiled among multiple human cancer cells. To determine whether they play a role in the activation of pAKT, MER and TYRO3 were selectively depleted by small, interfering RNA knockdown. In addition, using AKT phosphorylation as a readout, a high-throughput cell-based assay was established in G361 cells for evaluation of the potency of potential inhibitors of MER pathway activation.
We demonstrated that high levels of MER and TYRO3, but not AXL, were expressed in G361 cells. In these cells, pAKT was induced by GAS6 treatment, which could be reversed by AXL/MER inhibitors. We showed that GAS6-induced pAKT is only dependent on MER kinase, but not TYRO3, in G361 cells. Furthermore, we observed a correlation in potency between inhibition of pAKT in G361 cells and pMER in MER-overexpressing Ba/F3 cells by these inhibitors.
In summary, we have demonstrated that GAS6-induced pAKT is a possible pharmacodynamic marker for the inhibition of MER kinase, and we have successfully developed a cell-based functional assay for screening small-molecule inhibitors of MER kinase for potential therapeutic utility in treating GAS6/MER-deregulated human cancers.
Abnormalities in receptor tyrosine kinases are involved in a wide range of important biological activities in cancer, including cell proliferation, differentiation, and drug resistance . The TAM family of receptor tyrosine kinases includes 3 members: TYRO3, AXL, and MER . Binding of ligands to the these receptors was reported to lead to activation of the TAM kinases, as well as PI3K/AKT, RAS/RAF/MAPK, and JAK/STAT signaling pathways in human cancer cells [2,3,4]. TAM activation and signaling have been involved in multiple cellular functions, including cell growth arrest, cell survival, cell proliferation, cell adhesion, and inflammation [4, 5]. In addition, TAM activation was shown to regulate innate immunity including inflammatory pathways in dendritic cells and macrophages, clearance of apoptotic cells, and differentiation of natural killer cells [2,3,4,5,6,7,8].
Among the 3 TAM family members, AXL has been an attractive target for the treatment of cancer [9, 10]. Both small-molecule AXL kinase inhibitors and biological reagents that block the interaction between growth arrest–specific protein 6 (GAS6) and AXL have been reported at various stages of drug development . Stimulation of melanoma cells with GAS6 has been reported to activate several downstream signaling pathways including MAPK, AKT, and JAK/STAT. MER tyrosine kinase inhibition via small hairpin RNA reduced downstream signaling and inhibited tumor growth in an animal model, suggesting that MER kinase may be an attractive target for the treatment of human cancers . MER expression has been reported in a variety of tumors, including melanoma and pre–B-cell acute lymphoblastic leukemia [5, 13, 14], and ectopic expression of MER in lymphocytes in transgenic mice promotes the development of leukemia/lymphoma [5, 13]. MER is also implicated in other human conditions, such as autoimmune disease and thrombosis .
Extensive research has been conducted to identify MER-selective small-molecule inhibitors; for example, Graham et al. reported on the MER inhibitors UNC569, UNC1063, and UNC2025 by comparing the levels of phosphorylated MER (pMER) in cancer cells treated with pervanadate [15,16,17,18]. MER phosphorylation is dependent on binding of its ligand GAS6 or protein S [19, 20]; however, ligand-activated pMER is often unstable and difficult to detect without pervanadate pretreatment in human cancer cells, impeding the development of a selective MER kinase inhibitor . Therefore, it is important to identify a specific pharmacodynamic (PD) marker to monitor MER kinase activity in human cancer cells.
In this study, we profile the expression of MER, TYRO3, and AXL among multiple human cancer cells, and assess induction of phosphorylated AKT (pAKT) by GAS6 and reversal by AXL/MER inhibitors in human melanoma G361 cells that were found to express high levels of MER and TYRO3, but not AXL. We demonstrate that GAS6-induced pAKT is a possible PD marker for the inhibition of MER kinase in G361 cells, and developed a cell-based functional assay for screening small-molecule inhibitors of MER kinase for potential therapeutic utility in treating GAS6/MER-deregulated human cancers.
Materials and methods
HeLa, DU145, THP-1, RKO, SKM1, A549, OCI-LY3, G361, and HL60 human cancer cell lines were obtained from ATCC (Manassas, VA, USA). Roswell Park Memorial Institute (RPMI) 1640 medium, penicillin-streptomycin and 0.05% trypsin were from Gibco (Carlsbad, CA, USA). Heat-inactivated fetal bovine serum (FBS) was purchased from Hyclone (South Logan, UT, USA). Anti-pAKT (S473) #9271, anti-AXL (C44G1) #4566, anti-MER (D21F11) #4319, anti-TYRO3 (D38C6) #5585, and anti-rabbit Alexa 488 antibody were purchased from Cell Signaling Technology (Danvers, MA, USA).
Human cancer cells were grown in RPMI with 10% heat-inactivated FBS plus 1% penicillin-streptomycin at 37 °C with 5% CO2. All human cancer cell lines were split every 3 to 4 days using 0.05% Trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA).
Small, interfering RNA (siRNA) reagents to knock down each individual gene were from Dharmacon (Lafayette, CO, USA). For each transfection, 30 pmol of siRNAs (a mixture of 4 different siRNAs per gene) were transfected into cells using RNAiMax (Invitrogen, Waltham, MA, USA) with 2.5 mL of growth medium according to the manufacturer’s protocol. Knockdown efficiency was examined after 72 h by Western blotting.
TAM kinase assay
The assay buffer contained 50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM ethylene glycol tetraacetic acid, 0.01% NP-40, and 2 mM dithiothreitol. Test inhibitors (0.5 μL) dissolved in dimethyl sulfoxide (DMSO; 2.5% final concentration) were transferred to white 384-well assay plates (Greiner LUMITRAC™ plates, Sigma-Aldrich, St Louis, MO, USA). Enzyme solutions of 13.8 nM AXL (Life Technologies, Waltham, MA, USA, PV4275), 4.1 nM MER (Life Technologies, PV4112), or 0.366 nM TYRO3 (Life Technologies, PR7480A) were prepared in assay buffer. A 1 mM stock solution of peptide substrate Biotin-EQEDEPEGDYFEWLE-amide (Quality Controlled Biochemicals, Hopkinton, MA, USA) dissolved in DMSO was diluted to 1 μM in assay buffer containing 100 μM ATP (for AXL and MER assays) or 20 μM ATP (for TYRO3 assay).
Next, 10 μL enzyme solution (or assay buffer for the enzyme blank) was added to the appropriate wells in each plate, and 10 μL/well substrate solution was added to initiate the reaction. The plate was protected from light and incubated at room temperature for 1 h. The reaction was stopped by adding 10 μL detection solution containing 50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 0.05% bovine serum albumin (BSA), 45 mM EDTA, 180 nM streptavidin-allophycocyanin (Perkin Elmer, Waltham, MA, USA, CR130-100) and 3 nM Eu-W1024 anti-phosphotyrosine PY20 (Perkin Elmer, AD0067). The plate was incubated for 1 h at room temperature, and homogenous time-resolved fluorescence signal was measured on a PHERAstar FS plate reader (BMG LABTECH, Cary, NC, USA). Percentage inhibition was calculated for each concentration, and half-maximal inhibitory concentration (IC50) values were generated from curve fitting with GraphPad Prism software.
Cells were lysed in radioimmune precipitation assay buffer containing halt protease and phosphatase inhibitor mixture (Thermo Scientific, Waltham, MA, USA). Lysates were spun at 16,000 g at 4 °C for 30 min and normalized for protein concentration. For Western blotting, the protein concentration was determined and the lysates adjusted so that 50 μg was loaded per lane. Total cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred to nitrocellulose membranes (Invitrogen). Membranes were blocked in phosphate-buffered saline (PBS) plus 0.1% (v/v) Tween 20 (PBS-T) and 4% (w/v) nonfat dry milk (Bio-Rad, Hercules, CA, USA) for 1 h on a shaker at room temperature. Primary antibodies were added to the blocking solution at 1:1000 (MER, AXL, or TYRO3) and 1:10,000 (GAPDH, Cell Signaling Technology, catalog no. 2118S) dilutions and incubated and rocked overnight at 4 °C. Immunoblots were washed 3 times for 5 min each with PBS-T, and the secondary antibody was added at a 1:10,000 dilution into PBS-T milk for 1 h on a shaker at room temperature. After several washes, enhanced chemiluminescence reactions were performed according to the manufacturer’s recommendations (Supersignal West Dura extended duration substrate, Thermo Scientific).
pAKT high-content imaging assays and data analysis
G361 cells at 2 × 104 were plated in a black-walled, clear-bottom, 96-well tissue culture plate in 100 μL of growth media and incubated at 37 °C with 5% CO2 overnight. Cells were treated with AXL/MER inhibitors for 1 h followed by 2 μg/mL GAS6 (R&D Systems, Minneapolis, MN, USA) to activate the MER signaling pathway for 20 min, then fixed with 4% formaldehyde at room temperature for 30 min. Fixed G361 cells were permeabilized by incubating with 20 mL of permeabilization buffer (0.2% Triton X-100 in Dulbecco’s PBS [DPBS]) for 10 min at room temperature, blocked by incubation in blocking buffer (0.1% BSA in DPBS) for 30 min at room temperature, and stained with primary anti-pAKT antibody (1:300 in blocking buffer) at 4 °C overnight. G361 cells were then washed 3 times with DPBS and stained with the secondary antibody (1:1000 in blocking buffer) together with 5 mg/mL of Hoechst 33342 for 2 h at room temperature.
The Cellomics ArrayScan VTI system (Cellomics, Pittsburgh, PA, USA) was used to acquire and analyze images using the Cell Health Profiling BioApplication. The XF100-Hoechst [365(50)/535(45)] and XF100-FITC [475(40)/535(45)] filters were used with an X-Cite 120Q excitation light source to collect images of the Hoechst and fluorescein isothiocyanate (FITC) channels (Lumen Dynamics, Mississauga, ON, Canada). Images of 500 cells were captured for each well. Images in the Hoechst channel were used to identify cells with a fixed threshold. A circle was drawn with a radius of 40 pixels outside the cell border, and the total intensities of the FITC channel inside the circle were used to plot graphs. Luminescence values were used to calculate the inhibition of pAKT relative to DMSO-treated cells (0% inhibition). IC50 was further calculated.
pMER ELISA assay for MER-HA overexpressing Ba/F3 cells
The cytoplasmic domain of MER fused with dimerization sequence and HA tag was cloned into a pMSCV vector with a puromycin-resistance marker to generate the construct by electroporation. Single clones that were interleukin 3–independent and puromycin-resistant were selected and characterized. Cells with stable expression of MER were selected and designated MER-overexpressing Ba/F3 cells. An R&D enzyme-linked immunosorbent assay (ELISA) plate was coated with anti-HA (H3663, 1 μg/mL, 100 μL/well) overnight at 4 °C. Ba/F3-MER cells at 1.25 × 105 were treated with AXL/MER inhibitor for 1 h, before being added with 100 μL lysis buffer. Then 100 μL Ba/F3-MER cell lysis was added to the ELISA plate and incubated for 2 h. Next, 50 μL Eu-labeled anti–P-tyrosine antibodies (50 ng/well, PY-20) were added and incubated for 2 h at room temperature (with slow shaking), then the plate was washed 4 to 6 times. Finally, 200 μL DELFIA enhancement solution was added to each well and incubated for 15 min at room temperature, followed by measuring time-resolved fluorescence.
For TAM kinase assays, the average values of G361 cells stimulated with 2 μg/mL GAS6 in the presence of 0.2% DMSO were used as the positive control. Unstimulated cells containing 0.2% DMSO were used as the negative control. Results were plotted as mean total intensity. The IC50 was defined as the concentration of test inhibitor corresponding to 50% inhibition derived from the 11-point fitted curve as determined using a 4-parameter logistic regression model. Statistical analyses were performed using GraphPad Prism (v 6.01). Student’s t tests were performed to statistically analyze the results, with p < 0.05 considered significant. All graphical data were presented as mean ± standard deviation.
GAS6 induces pAKT in human melanoma G361 cells
To identify the potential downstream component of the GAS6/MER pathway, we compared the expression of MER, AXL, and TYRO3 among various human cancer cell lines including HeLa, DU145, THP-1, RKO, SKM1, A549, OCI-LY3, G361, and HL60 (Fig. 1a). A high expression of MER and TYRO3 kinases, but not AXL, was observed in G361 cells. In contrast, other human cancer cell lines did not show a robust expression of MER kinase. Next, we tested whether GAS6 could induce significant expression of pAKT in G361 cells. Using high-content imaging analysis, a 3- to 4-fold increase of pAKT was observed after 20 min of treatment with 2 μg/mL GAS6, and this increase could be reversed by AXL/MER inhibitor (Fig. 1b and c). Therefore, G361 cells were chosen for GAS6/MER cellular assay development and PD marker validation.
MER kinase is required for GAS6-induced pAKT in G361 cells
Since G361 cells showed high expression of both MER and TYRO3 kinases, GAS6-induced pAKT could occur through either kinase. To investigate the role of MER kinase in regulating GAS6-induced pAKT, we knocked down MER and TYRO3 kinases in G361 cells. siMER, siAXL, and siTYRO3 showed a robust reduction of MER, AXL, and TYRO3 expression in H1299 cells, and MER and TYRO3 in G361 cells (which do not express AXL kinase) (Fig. 2a). The knockdown of each gene and levels of pAKT were analyzed via high-content imaging assays. The pAKT levels in G361 cells increased 3- to 4-fold after a 15-min treatment with 2 μg/mL GAS6, which was reversed either by AXL/MER inhibitor 3 or by siMER, but not siNTC or siAXL (Fig. 2b). In contrast, the increase of pAKT levels was not reversed by siTYRO3-mediated knockdown of TYRO3 (Fig. 2c). These data demonstrate that MER kinase but not TYRO3 kinase is required for GAS6-induced pAKT in human melanoma G361 cells.
AXL/MER inhibitors reduce GAS6-stimulated pAKT signal in a concentration-dependent manner
Given the specific role of MER kinase in G361 cells, we investigated whether GAS6-stimulated pAKT could be developed as a cellular assay. Four AXL/MER inhibitors with varied biochemical potencies (data not shown) were tested in the high-content imaging assays in the presence of GAS6. The imaging data showed AXL/MER inhibitors reduced GAS6-stimulated pAKT in a concentration-dependent manner (Fig. 3a). The IC50s required for pAKT inhibition from these 4 AXL/MER inhibitors were generated and shown in Fig. 3b, suggesting a potential GAS6/MER cellular assay for testing AXL/MER inhibitors.
pAKT inhibition in GAS6-treated G361 cells may represent pMER inhibition in MER-overexpressed Ba/F3 cells
To further confirm whether pAKT inhibition correlates with the activity of the GAS6-stimulated MER pathway in G361 cells, we compared the potency of AXL/MER inhibitors between pAKT inhibition in GAS6-treated G361 cells and pMER inhibition in MER-overexpressed Ba/F3 cells. An example shown in Fig. 4a demonstrated that AXL/MER inhibitors reduced pAKT in GAS6-treated G361 cells with a similar trend of pMER inhibition in MER-overexpressed Ba/F3 cells. The calculated IC50s of 8 different AXL/MER inhibitors from these 2 assays are shown in Fig. 4b. A correlation of the 2 activities was graphed and shown in Fig. 4c. These data suggest a potential correlation between pAKT inhibition in GAS6-treated G361 cells and pMER inhibition in MER-overexpressed Ba/F3 cells.
MER kinase selective inhibitor reduces GAS6-stimulated AKT phosphorylation in G361 but not H1299 cells
In contrast to G361 cells, H1299 cells exhibit AXL expression (Fig. 2a), and it has been shown previously that pAKT is activated by the GAS6-stimulated AXL pathway in H1299 cells . To test the selectivity of the MER inhibitor, we compared pAKT inhibition between H1299 and G361 cells with AXL/MER inhibitors that showed different potencies in AXL/MER enzymatic assays. Whereas most AXL/MER inhibitors showed similar potency in pAKT inhibition between G361 cells and H1299 cells due to their dual biochemical activities (Fig. 5a and b), inhibitor 11 exhibited MER in vitro kinase inhibition with an IC50 of 67 nM and AXL in vitro kinase inhibition with an IC50 of 1814 nM. Consistent with this result, pAKT inhibition occurred at an IC50 of 95 nM in G361 cells, and an IC50 of 1161 nM in H1299 cells (Fig. 5b). These results suggest that pAKT can be induced via both AXL and MER kinases in H1299 but only MER kinase in G361 cells, and therefore may be used as models for differentiating cellular AXL and MER activity.
The GAS6/MER signaling pathway has emerged as a therapeutic target for human cancer and immune disorders [2, 4]. Identification of a PD marker for MER kinase and establishing a robust endogenous cellular system would be important to allow evaluation of the potency of GAS6/MER pathway inhibitors. AKT has been reported as a key downstream component in the GAS6/AXL pathway, and its phosphorylation may be used as an indication of AXL activation . However, the downstream component of the GAS6/MER pathway has not been elucidated. In our study, we identified the human melanoma G361 cell line as a good model system to assay the activation of the MER signaling pathway. We profiled the expression of MER among multiple human cancer cells and found that MER and TYRO3, but not AXL, show high levels of protein expression in G361 cells. This is consistent with earlier results demonstrating that melanoma cells expressed very little AXL and relied more on the MER and TYRO3 kinases . In G361 cells, pAKT is induced by GAS6 treatment and the induction of pAKT can be reversed by AXL/MER inhibitors. We also demonstrated that GAS6-induced pAKT is only dependent on MER kinase, but not TYRO3 via siRNA study. We focused not only on MER expression level in various human cancer cell lines but also on whether their GAS6-induced AKT phosphorylation was dependent on MER receptor status; this was a key factor that led to identifying G361 cells as a suitable cell line for the endogenous MER cellular assay (Fig. 6).
Recently, efforts have been made to identify MER-selective small-molecule inhibitors for human cancer [15,16,17]. However, one hurdle in the development of a selective MER kinase inhibitor is that ligand-activated pMER is unstable and difficult to observe without pervanadate pretreatment. For most current MER-selective inhibitors like UNC569, UNC2025, or UNC3133, their cellular activities were measured under pervanadate pretreatment in human cancer cells [15,16,17]. However, pervanadate pretreatment may interfere with cellular activity; hence, it is necessary to identify a PD marker for MER kinase and establish a robust endogenous cellular system to evaluate MER kinase activity. We identified that GAS6-induced AKT phosphorylation is dependent on the MER receptor in G361 cells and further used the high-throughput high-content imaging system to evaluate compound inhibitor potency in inhibiting MER pathway activation.
pAKT is an important biomarker for human cancer [22,23,24,25]. To establish pAKT as a direct phosphorylation target of MER kinase, we developed a MER cellular assay and compared the inhibition of MER activation and AKT phosphorylation. As endogenous pMER is difficult to detect, we measured the pMER readout in MER-overexpressed Ba/F3 cells. We tested 8 different AXL/MER inhibitors and were able to demonstrate correlation between pAKT inhibition in GAS6-stimulated G361 cells and pMER inhibition in MER-overexpressed Ba/F3 cells. This suggests that pAKT in GAS6-stimulated G361 cells can recapitulate endogenous pMER activity to a certain degree.
In summary, pAKT was identified as a robust PD marker and a cellular high-throughput high-content imaging assay was established to assess inhibition of GAS6-induced MER pathway activation. These represent useful tools for successful screening and optimization of small molecules for the treatment of GAS6/MER-driven diseases.
Availability of data and materials
All data are included in the article.
Bovine serum albumin
Dulbecco’s phosphate-buffered saline
Enzyme-linked immunosorbent assay
Fetal bovine serum
Growth arrest–specific protein 6
- IC50 :
Half-maximal inhibitory concentration
Roswell Park Memorial Institute
Small, interfering RNA
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.
Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35–83.
Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8:327–36.
Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14:769–85.
Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, et al. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. 2013;32:5359–68.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018;11:8.
Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.
Lemke G. How macrophages deal with death. Nat Rev Immunol. 2019;19:539–49.
Sadahiro H, Kang KD, Gibson JT, Minata M, Yu H, Shi J, et al. Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma. Cancer Res. 2018;78:3002–13.
Oien DB, Garay T, Eckstein S, Chien J. Cisplatin and pemetrexed activate AXL and AXL inhibitor BGB324 enhances mesothelioma cell death from chemotherapy. Front Pharmacol. 2017;8:970.
Myers SH, Brunton VG, Unciti-Broceta A. AXL inhibitors in cancer: a medicinal chemistry perspective. J Med Chem. 2016;59:3593–608.
Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest. 2013;123:2257–67.
Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 2013;32:3420–31.
Shi C, Li X, Wang X, Ding N, Ping L, Shi Y, et al. The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma. J Hematol Oncol. 2018;11:43.
Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, et al. UNC569, a novel small-molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013;12:2367–77.
Liu J, Zhang W, Stashko MA, Deryckere D, Cummings CT, Hunter D, et al. UNC1062, a new and potent Mer inhibitor. Eur J Med Chem. 2013;65:83–93.
Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem. 2014;57:7031–41.
DeRyckere D, Lee-Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, et al. UNC2025, a MERTK small-molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clin Cancer Res. 2017;23:1481–92.
Ubil E, Caskey L, Holtzhausen A, Hunter D, Story C, Earp HS. Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest. 2018;128:2356–69.
Benzakour O, Gely A, Lara R, Coronas V. Gas-6 and protein S: vitamin K-dependent factors and ligands for the TAM tyrosine kinase receptors family. Med Sci (Paris). 2007;23:826–33.
Tang H, Yang J, Shen DR, Calambur D, Witmer M, Wu S, et al. High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors. Assay Drug Dev Technol. 2014;12:80–6.
Massihnia D, Avan A, Funel N, Maftouh M, van Krieken A, Granchi C, et al. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. J Hematol Oncol. 2017;10:9.
El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, et al. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10:19.
Southworth T, Mason S, Bell A, Ramis I, Calbet M, Domenech A, et al. PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge. Biomark Res. 2018;6:14.
Strickland AL, Rivera G, Lucas E, John G, Cuevas I, Castrillon DH. PI3K pathway effectors pAKT and FOXO1 as novel markers of endometrioid intraepithelial neoplasia. Int J Gynecol Pathol. 2019;38:503–13.
This manuscript is dedicated to the memory of our friend and colleague Dr. Yun-long Li, a creative chemist who was committed to bringing innovative medicines to cancer patients. Editorial assistance was provided by Abigail Marmont, PhD, CMPP, of Envision Pharma Group, Inc. (Philadelphia, PA), and funded by Incyte Corporation.
The study was funded, sponsored, and designed by Incyte Corporation (Wilmington, DE, USA). The data were analyzed and interpreted by the sponsors in collaboration with all of the authors.
Ethics approval and consent to participate
Consent for publication
Yaoyu Chen, MF, MP, JL, YL, MY, RW, XW, WY, and Yingnan Chen are employees of Incyte Research Institute, Incyte Corporation.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Chen, Y., Favata, M., Pusey, M. et al. Identification of pAKT as a pharmacodynamic marker for MER kinase in human melanoma G361 cells. Biomark Res 8, 4 (2020). https://doi.org/10.1186/s40364-020-0184-9
- MER kinase
- Phosphorylated AKT